Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

The purpose of this study is to assess the safety, tolerability, and pharmacokinetics of AZD0233 following single and multiple ascending dose (SAD and MAD) administration in healthy participants

Next Previous
Trial Profile

The purpose of this study is to assess the safety, tolerability, and pharmacokinetics of AZD0233 following single and multiple ascending dose (SAD and MAD) administration in healthy participants

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 23 May 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs AZD 0233 (Primary)
  • Indications Dilated cardiomyopathy
  • Focus Adverse reactions; First in man
  • Sponsors AstraZeneca

Most Recent Events

  • 16 May 2025 Planned End Date changed from 10 Jun 2025 to 16 Sep 2025.
  • 16 May 2025 Planned primary completion date changed from 10 Jun 2025 to 16 Sep 2025.
  • 25 Apr 2025 Planned number of patients changed from 96 to 88.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top